News
Exicure
XCUR · NASDAQ
$0.9987−$0.0313 (−3.04%)TodayMarket closed ·
Prev close $1.03
Latest news
- News
12 Health Care Stocks Moving In Monday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's After-Market Session
- News
12 Health Care Stocks Moving In Thursday's After-Market Session
- News
Exicure Q1 EPS $(0.29) Down From $0.49 YoY
- Press releaseGlobe Newswire
Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- NewsAvi Kapoor
Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session
- NewsAvi Kapoor
Why MindWalk Holdings Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
Crude Oil Down 1%; AutoZone Shares Dip After Q1 Results
- News
12 Health Care Stocks Moving In Tuesday's Intraday Session
- NewsVandana Singh
Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial
- NewsAvi Kapoor
Dow Surges Over 100 Points; Campbell's Posts Upbeat Earnings
- News
Market-Moving News for December 9th
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseBusiness Wire
Halper Sadeh LLC Encourages Exicure, Inc. Shareholders to Contact the Firm to Discuss Their Rights
- News
Exicure Says Ongoing Phase 2 Study Of Burixafor In Autologous Stem Cell Transplant For Multiple Myeloma Nears Key Readout
- Press releaseGlobe Newswire
Exicure Highlights Recent Achievements and Near-term Strategic Priorities
- Press releaseBusiness Wire
Exicure, Inc. Reports Second Quarter 2025 Financial Results
- Press releaseBusiness Wire
Exicure, Inc. (Nasdaq: XCUR) Regains Compliance with Nasdaq Filing Requirements
- Press releaseBusiness Wire
Exicure Completes the Last Patient, Last Visit in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
- Press releaseBusiness Wire
Exicure, Inc. Reports First Quarter 2025 Financial Results
- Press releaseBusiness Wire
Exicure, Inc. Received Nasdaq Delinquency Notice on Late Filing of its Form 10-Q
- Press releaseBusiness Wire
Exicure Completes Patient Enrollment in Phase 2 Study of GPC-100 for Stem Cell Mobilization in Multiple Myeloma Patients Undergoing Autologous Transplant
- Press releaseBusiness Wire
Exicure, Inc. (Nasdaq: XCUR) Nears Completion of Phase 2 Study of GPC-100 in Multiple Myeloma
- Press releaseBusiness Wire
Exicure, Inc. (Nasdaq: XCUR) Announces Their Next Step in Planning for a New Clinical Trial in Acute Myeloid Leukemia (AML)
- News
12 Health Care Stocks Moving In Tuesday's After-Market Session
- Press releaseBusiness Wire
Exicure, Inc. Reports Full Year 2024 Financial Results
- Press releaseBusiness Wire
Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia
- News
12 Health Care Stocks Moving In Thursday's Pre-Market Session
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseBusiness Wire
Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.
- Press releaseBusiness Wire
Exicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in Biotech
- News
Exicure Announces Shareholders Approve $8.7M Equity Financing From HiTron Systems
- Press releaseBusiness Wire
Exicure, Inc. Announces Shareholders Approve the $8.7 Million Equity Financing and Reports Executive Management and Board Changes
- NewsAvi Kapoor
Why Marvell Technology Shares Are Trading Higher By Around 13%; Here Are 20 Stocks Moving Premarket
- News
12 Health Care Stocks Moving In Monday's Pre-Market Session
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- Press releaseBusiness Wire
Exicure, Inc. Enters into Purchase Agreements for $1.3 Million and $8.7 Million Equity Financing and Reports Third Quarter 2024 Financial Results
- News
12 Health Care Stocks Moving In Thursday's Intraday Session
- NewsAvi Kapoor
Why Exicure Shares Are Trading Higher By Around 180%; Here Are 20 Stocks Moving Premarket
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.